Kyung Hee University has disclosed microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors acting as prostaglandin E2 (PGE2) production inhibitors reported to be useful for the treatment of asthma, atherosclerosis, diabetes, pain, osteoporosis, bursitis, infections and cancer.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Glyprovac LLC US$467,000 to develop a maternal vaccine that targets Escherichia coli, a bacterial species responsible for a large portion of neonatal sepsis infections.
The transcription of ribosomal RNA by RNA Polymerase I (Pol I) is an essential step for cells to grow and thus is considered a therapeutic target for cancer treatment.
Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
Hepatocellular carcinoma (HCC) is a complex disease where both the activation of the cyclic GMP-AMP synthase-stimulator of the interferon gene (cGAS-STING) pathway and the induction of immunogenic cell death (ICD) have proven effective immunotherapeutic strategies in some instances.
Ariceum Therapeutics GmbH has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial (CITADEL-123) of 123I-ATT-001, its iodine-123 labeled PARP inhibitor, in patients with recurrent glioblastoma. The study is expected to begin in the U.K. in June of 2024.
Dyadic International Inc.'s Dutch subsidiary, Dyadic Nederland BV, has entered into a strategic partnership agreement and collaboration with Rabian BV to develop efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
Long-chain fatty acid beta-oxidation disorders (lcFAOD) are a group of inherited metabolic diseases, characterized by the accumulation of disease-specific acyl-CoAs reflecting the enzyme deficiency. The exact consequence of accumulating lcFAO-intermediates and their influence on cellular lipid homeostasis in patients with these diseases is unknown.
Researchers from Capital Medical University have presented preclinical data for the novel PDZ-binding kinase (PBK) inhibitor, HI-TOPK-032, which is being developed for the treatment of cancer. The study aimed to assess the effects of the candidate on NK-92MI cell infiltration into ovarian tumors.
RSS
